title: Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.
abstract: OBJECTIVE
  To investigate whether microRNA-21 was involved in mediating the chemoresistance of prostate cancer cells to docetaxel.
  
  
  METHODS
  A microarray technique was used to determine the miRNA profile in docetaxel-resistant PC3 cells. Real-time PCR was used to confirm the array results. miR-21 mimics and inhibitors were synthesized and introduced to cells using Lipofectamine 2000. Cell proliferation was examined with the CCK-8 assay. Luciferase reporter containing PDCD 3'UTR was constructed and the activity was detected by a dual luciferase assay. PDCD4 protein expression was evaluated using Western blot.
  
  
  RESULTS
  A docetaxel-resistant prostate cancer PC3 cell line (PC3R) was established . Using microarrays, miR-21 was found to be up-regulated in PC3R cells. Ectopic expression of miR-21 increased the resistance to docetaxel in PC3 wild type cells. In contrast, silencing of miR-21 in PC3R cells sensitized the cells to docetaxel. The IC(50) values for miR-21-silencing cells and control cells were 28.31 and 35.89 nmol/L, respectively. PDCD4, a direct target gene of miR-21, could mediate chemoresistance to docetaxel in PC3 cells.
  
  
  CONCLUSIONS
  Our findings suggest that miR-21 contributed to the resistance of PC3 cells to docetaxel, and that targeting miR-21 may offer a promising therapeutic approach in sensitizing prostate cancer to docetaxel treatment.
authors.affiliation: Department of Urology, Cancer Hospital, Fudan University, Shanghai, China.
authors.forename: Guo-hai
authors.initials: GH
authors.lastname: Shi
authors.forename: Ding-wei
authors.initials: DW
authors.lastname: Ye
authors.forename: Xu-dong
authors.initials: XD
authors.lastname: Yao
authors.forename: Shi-ling
authors.initials: SL
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.forename: Hai-liang
authors.initials: HL
authors.lastname: Zhang
authors.forename: Yi-jun
authors.initials: YJ
authors.lastname: Shen
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhu
authors.forename: Yi-ping
authors.initials: YP
authors.lastname: Zhu
authors.forename: Wen-jun
authors.initials: WJ
authors.lastname: Xiao
authors.forename: Chun-guang
authors.initials: CG
authors.lastname: Ma
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D051017:Apoptosis Regulatory Proteins / Q000235:genetics; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D006801:Humans; D020128:Inhibitory Concentration 50; D008055:Lipids; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016601:RNA-Binding Proteins / Q000235:genetics; D043823:Taxoids / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D008055:Lipids; C086724:Lipofectamine; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; C114487:PDCD4 protein, human; D016601:RNA-Binding Proteins; D043823:Taxoids; D000077143:Docetaxel